Abstract
Cardiovascular diseases as hypertension, angina and/or supraventricular arrhythmias are among the most important death causes in the world. For the treatment of heart pathologies, calcium channel entry blockers are very important drugs, owing to their therapeutic versatility. Although few calcium antagonists described until today are structurally related to diltiazem and to the benzothiazepine class, the still high pharmaceutical interest on diltiazem analogues justifies this review. Diltiazem and its first analogues developed in the early 70s became popular in the 80s, and were pharmacologically characterized for a long time. It is in the 90s that several research groups carried out structural variations identifying novel scaffolds for diltiazem-related compounds, with significant calcium antagonist behaviour. Recently, a series of thiazino-oxadiazolone derivatives were identified as potent and selective antagonists for calcium influx into cardiac cells, and they were subsequently used to search for novel chemotypes by means of virtual screening techniques. The resulting hits could open interesting perspectives for the development of drugs to treat cardiovascular diseases. In the present review, an updated collection of diltiazem analogues is reported over the last ten years. The chemical structure and the structure activity relationships will be given, with additional mention to the potential therapeutic applications.
Current Medicinal Chemistry
Title: Diltiazem Analogues: The Last Ten Years on Structure Activity Relationships
Volume: 14 Issue: 3
Author(s): Roberta Budriesi, Barbara Cosimelli, Pierfranco Ioan, Emanuele Carosati, Maria P. Ugenti and Rraffaella Spisani
Affiliation:
Abstract: Cardiovascular diseases as hypertension, angina and/or supraventricular arrhythmias are among the most important death causes in the world. For the treatment of heart pathologies, calcium channel entry blockers are very important drugs, owing to their therapeutic versatility. Although few calcium antagonists described until today are structurally related to diltiazem and to the benzothiazepine class, the still high pharmaceutical interest on diltiazem analogues justifies this review. Diltiazem and its first analogues developed in the early 70s became popular in the 80s, and were pharmacologically characterized for a long time. It is in the 90s that several research groups carried out structural variations identifying novel scaffolds for diltiazem-related compounds, with significant calcium antagonist behaviour. Recently, a series of thiazino-oxadiazolone derivatives were identified as potent and selective antagonists for calcium influx into cardiac cells, and they were subsequently used to search for novel chemotypes by means of virtual screening techniques. The resulting hits could open interesting perspectives for the development of drugs to treat cardiovascular diseases. In the present review, an updated collection of diltiazem analogues is reported over the last ten years. The chemical structure and the structure activity relationships will be given, with additional mention to the potential therapeutic applications.
Export Options
About this article
Cite this article as:
Budriesi Roberta, Cosimelli Barbara, Ioan Pierfranco, Carosati Emanuele, Ugenti P. Maria and Spisani Rraffaella, Diltiazem Analogues: The Last Ten Years on Structure Activity Relationships, Current Medicinal Chemistry 2007; 14 (3) . https://dx.doi.org/10.2174/092986707779941122
DOI https://dx.doi.org/10.2174/092986707779941122 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Maternal Obesity and Gestational Diabetes Mellitus on the Placenta: Current Knowledge and Targets for Therapeutic Interventions
Current Vascular Pharmacology Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Impact of the Presence of Select Cardiovascular Risk Factors on Cognitive Changes among Dementia Subtypes
Current Alzheimer Research The Influence of Fatty Acids on Metoprolol - Human Serum Albumin Interaction in Low Affinity Binding Sites: A Multifactorial NMR Approach
Protein & Peptide Letters Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery The Relationship Between Hypertensive Retinopathy and Angiotensin Converting Enzyme Gene Polymorphism
Cardiovascular & Hematological Disorders-Drug Targets Disturbed Tryptophan Metabolism in Cardiovascular Disease
Current Medicinal Chemistry A panoramic view of chronic liver diseases and natural remedies reported in Traditional Persian Medicine
Current Pharmaceutical Design Angiotensin II Regulates Vascular and Endothelial Dysfunction: Recent Topics of Angiotensin II Type-1 Receptor Signaling in the Vasculature
Current Vascular Pharmacology Safety Aspects of Statins: Which Factors Create the Adverse Effects of Statins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Challenges in Diagnosing Cerebral Lacunar Infarcts
Current Medical Imaging Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design Have We New Therapeutic Strategies in the Treatment of Renovascular Nephropathy?
Current Vascular Pharmacology Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf
Current Vascular Pharmacology Editorial [ Hot Topic: The Blood-Brain Barrier as a Cause of Disease (Executive Editor: William A. Banks) ]
Current Pharmaceutical Design Neurotoxicity of Ecstasy (MDMA): An Overview
Current Pharmaceutical Biotechnology Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond
Current Medicinal Chemistry Monitoring and Surveillance of Obesity in the United States
Current Nutrition & Food Science